A Phase 1 interventional study of Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 5 mg tirzepatide injection administered subcutaneously (SC).
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞])
PK: AUC (0-∞) of Tirzepatide excreted in Breastmilk
Time frame: Predose, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 168, 336, 504, 672 hours post-dose
| Milestone | 5 mg Tirzepatide |
|---|---|
| Started | 11 |
| Received a dose of tirzepatide | 11 |
| Completed | 11 |
| Not completed | 0 |
PK: AUC (0-∞) of Tirzepatide excreted in Breastmilk
| nanogram*hours per milliliter (ng*h/mL) | 5 mg Tirzepatide |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞]) | NA ± NA |
Collected over Baseline to the end of follow-up (up to Day 29). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Event | 5 mg Tirzepatide |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 10/11 |
| NauseaGastrointestinal disorders | 9/11 |
| DiarrhoeaGastrointestinal disorders | 7/11 |
| HeadacheNervous system disorders | 5/11 |
| VomitingGastrointestinal disorders | 4/11 |
| FatigueGeneral disorders | 4/11 |
| Abdominal distensionGastrointestinal disorders | 3/11 |
| Abdominal discomfortGastrointestinal disorders | 2/11 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/11 |
| Abdominal painGastrointestinal disorders | 1/11 |
All enrolled participants.
| Age, Continuous(years) | 5 mg Tirzepatide |
|---|---|
| Mean | 32.7 ± 4.8 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide |
|---|---|
| Female | 11 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 2 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 5 mg Tirzepatide |
|---|---|
| United States | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Mar 2024, 7 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide